Clinical Trial Update: Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NKT2152 in combination with palbociclib and sasanlimab for advanced clear cell renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• NKT2152
• Palbociclib (palbociclib)
• Sasanlimab (sasanlimab)

Snippet

Sponsor: NiKang Therapeutics, Inc. | Conditions: ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: TERMINATED